Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
antifungal
Biotech
F2G, Shionogi prep regulatory push after antifungal passes ph. 3
F2G and Shionogi have released phase 3 data for olorofim demonstrating its non-inferiority compared with an existing drug for invasive aspergillosis.
Will Maddox
Jun 18, 2026 12:01am
Pulmocide pulls ph. 3 antifungal trial over mortality rate
Jan 7, 2026 10:57am
Basilea pens collab with US biotech to develop antifungal
Jan 7, 2026 7:05am
Basilea secures $39M as part of BARDA antifungal funding plan
Jul 8, 2025 3:52am
Newfound compound kills multi-drug-resistant fungi
Mar 19, 2025 12:00pm
Basilea opts not to take MRSA antibiotic into clinic
Feb 18, 2025 4:08am
